This project aims to provide timely, nonpartisan analysis of Congressional or administrative drug proposals as they are released. Each analysis will highlight Fund-supported research, frame the issue the policy is attempting to address, consider other relevant policy options with a focus on health equity, and interpret policy nuances for a wider audience. Final decisions on topics for each blog post will be decided jointly between the grantee and Fund staff, but may include proposals to eliminate the Average Manufacturer Price cap in Medicaid, analysis of the House Oversight investigation of AbbVie, or an evaluation of the President’s budget as it relates to drug pricing. The project also will convene two roundtables of academic researchers on drug pricing policy, focusing on areas like health equity or anticompetitive behavior, to translate current research into more digestible products.